Your browser doesn't support javascript.
The Brighton Collaboration standardized template for collection of key information for benefit-risk assessment of protein vaccines.
Kochhar, Sonali; Kim, Denny; Excler, Jean-Louis; Condit, Richard C; Robertson, James S; Drew, Stephen; Whelan, Mike; Wood, David; Fast, Patricia E; Gurwith, Marc; Klug, Bettina; Khuri-Bulos, Najwa; Smith, Emily R; Chen, Robert T.
  • Kochhar S; Global Healthcare Consulting, New Delhi, India; University of Washington, Seattle, WA, USA.
  • Kim D; Janssen Pharmaceuticals, Titusville, NJ, USA.
  • Excler JL; International Vaccine Institute, Seoul, Republic of Korea.
  • Condit RC; Department of Molecular Genetics and Microbiology, University of Florida, Gainesville, FL, USA.
  • Robertson JS; Independent Adviser, UK.
  • Drew S; Independent Adviser, USA.
  • Whelan M; Project Leader, CEPI, UK.
  • Wood D; Independent Adviser, UK.
  • Fast PE; International AIDS Vaccine Initiative, New York, NY, USA; Stanford School of Medicine, Palo Alto, CA, USA.
  • Gurwith M; Brighton Collaboration, a Program of the Task Force for Global Health, Decatur, GA, USA.
  • Klug B; Paul-Ehrlich-Institut, Federal Institute for Vaccines and Biomedicines, Langen, Germany.
  • Khuri-Bulos N; University of Jordan, Amman, Jordan.
  • Smith ER; Brighton Collaboration, a Program of the Task Force for Global Health, Decatur, GA, USA. Electronic address: brightoncollaborationv3swg@gmail.com.
  • Chen RT; Brighton Collaboration, a Program of the Task Force for Global Health, Decatur, GA, USA.
Vaccine ; 38(35): 5734-5739, 2020 07 31.
Article in English | MEDLINE | ID: covidwho-640754
ABSTRACT
Several protein vaccine candidates are among the COVID-19 vaccines in development. The Brighton Collaboration Viral Vector Vaccines Safety Working Group (V3SWG) has prepared a standardized template to describe the key considerations for the benefit-risk assessment of protein vaccines. This will help key stakeholders to assess potential safety issues and understand the benefit-risk of such a vaccine platform. The structured and standardized assessment provided by the template would also help contribute to improved public acceptance and communication of licensed protein vaccines.
Subject(s)
Keywords
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Viral Vaccines Type of study: Prognostic study Topics: Vaccines Limits: Humans Language: English Journal: Vaccine Year: 2020 Document Type: Article Affiliation country: J.vaccine.2020.06.044

Similar

MEDLINE
LILACS
LIS
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Viral Vaccines Type of study: Prognostic study Topics: Vaccines Limits: Humans Language: English Journal: Vaccine Year: 2020 Document Type: Article Affiliation country: J.vaccine.2020.06.044